Discussion
The protozoan parasite Trypanosoma brucei causes HumanAfricantrypanosomiasis (HAT), amajor health concern in sub-Saharan Africa with an estimated 50,000 cases and 60 million at risk of infection. Several drugs such as Melarsoprol and Eflornithine have been developed to treat HAT [1] [2] . However these drugs used have serioussideeffects,poorclinicaleffectand emerging drug resistance [3] [4] [5] [6] .A ccording to the research reported by Hwang et al. [7] ,as erieso fh alo-nitrobenzamides,which have two distinct features: apotentially electrophiliccenter and ahydrophobic sidec hain, inhibited Trypanosoma brucei proliferation with fairly good potency and had good selectivity against malaria and mammalian cells. Thetitle compound is an important intermediate in the preparation of halo-nitrobenzamides. The crystal structure of the title compound is only build up by the C 7 H 4 ClNO 4 molecules. The nitro group (O3-N1-O4) attached at C2 and the carboxyl group (O1-C7-O2) attached at C1 form dihedral angles of 34.18(10)°and 45.19(9)°with the benzene ring, respectively. In the carboxyl group, the two C-O bond lengths are nearly equal, at about 1.26 Å(for comparison atypical C-O single bond is 1.43 Å, and an average C-O double bond is 1.23 Å). The Hatom is evenly distributed on the two Oatoms;site occupancy factor is 0.5/0.5. Other bond lengths are 
